	US 12,215,129 B2
	Antibacterial cyclopeptides targeting acinetobacter and other gram-negative pathogens
Eric W. Schmidt, Salt Lake City, UT (US); Margo Haygood, Portland, OR (US); and Bailey Miller, Salt Lake City, UT (US)
Assigned to University of Utah Research Foundation, Salt Lake City, UT (US)
Appl. No. 18/034,670
Filed by UNIVERSITY OF UTAH RESEARCH FOUNDATION, Salt Lake City, UT (US)
PCT Filed Oct. 29, 2021, PCT No. PCT/US2021/057350 § 371(c)(1), (2) Date Apr. 28, 2023, PCT Pub. No. WO2022/094273, PCT Pub. Date May 5, 2022.
Claims priority of provisional application 63/187,816, filed on May 12, 2021.
Claims priority of provisional application 63/107,901, filed on Oct. 30, 2020.
Prior Publication US 2023/0391827 A1, Dec. 7, 2023
Int. Cl. C07K 11/02 (2006.01); A61P 31/04 (2006.01); A61K 38/00 (2006.01)

CPC C07K 11/02 (2013.01) [A61P 31/04 (2018.01); A61K 38/00 (2013.01)]

20 Claims

1. A compound having a structure represented by a formula:

wherein R¹is selected from C1-C24 alkyl and C2-C24 alkenyl

wherein each of R², R⁶, and R⁹is independently a side chain of a D-amino acid residue;

wherein R³is a polar uncharged side chain of an amino acid residue;

wherein R⁴is a hydrophobic side chain of an amino acid residue;

wherein R⁵is a side chain of an amino acid residue selected from cysteine, selenocysteine, glycine, and proline;

wherein R⁷is a side chain of a homo-amino acid residue selected from homoserine, homothreonine, homoasparagine, and homoglutamine;

wherein R⁸is a hydrophobic side chain of an amino acid residue;

wherein R¹⁰is an electrically charged side chain of an amino acid residue;

wherein each of R^11aand R^11bis independently selected from hydrogen and C1-C4 alkyl; and

wherein each of R¹², R¹³, and R¹⁴is independently selected from —OH, —SH, and —NH₂,

or a pharmaceutically acceptable salt thereof, provided that the compound does not have a structure represented by a formula:

wherein R⁴is valine, R⁶is D-alloisoleucine, R⁸is alanine, R^11ais methyl, R^11bis hydrogen, and R¹⁴is —OH.